A nurse is preparing to administer olanzapine extended release 210 mg IM to a client. Which of the following actions should the nurse take?
A.
Monitor the client’s sodium levels.
B.
Evaluate the client’s frequency of panic attacks.
C.
Inform the client that application site rash is common.
D.
Observe the client for 3 hr following administration of medication.
The Correct answer and Explanation is:
The correct answer is D. Observe the client for 3 hours following administration of medication.
Olanzapine extended-release injection is an atypical antipsychotic used primarily to manage symptoms of schizophrenia and bipolar disorder. When administered as an intramuscular (IM) injection, especially in its long-acting form, it carries risks that necessitate close observation following administration.
One of the most critical risks associated with olanzapine IM injections is post-injection delirium/sedation syndrome (PDSS). This syndrome can occur if the medication inadvertently enters the bloodstream too quickly, causing an overdose. PDSS may manifest as excessive sedation, dizziness, confusion, and in some cases, even coma. Therefore, close monitoring for at least 3 hours after administration is essential to ensure the client does not develop symptoms of PDSS, such as severe drowsiness or signs of altered consciousness. By observing the client for 3 hours, the healthcare team can promptly identify and respond to any adverse reactions.
Explanation of Other Options:
- A. Monitor the client’s sodium levels: Olanzapine is not known to significantly impact sodium levels, unlike other medications such as certain antidepressants or antidiuretic agents. Thus, routine monitoring of sodium is unnecessary when administering olanzapine IM.
- B. Evaluate the client’s frequency of panic attacks: While olanzapine may help stabilize mood disorders, panic attacks are typically treated with different classes of medications (e.g., SSRIs, benzodiazepines). Evaluating panic attack frequency is not directly related to the administration of olanzapine extended-release IM.
- C. Inform the client that application site rash is common: While injection site reactions can occur, severe or common rashes are not typical with olanzapine injections. Pain or irritation at the injection site is more common than rash development.
In summary, close observation for 3 hours after IM administration of olanzapine is a vital safety precaution to manage potential complications like PDSS.